Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Borealis-2: Apatorsen + Docetaxel in Urothelial Carcinoma
NCT01780545Phase 2Completed
- Start
- Apr 2013
- Primary completion
- Oct 2017
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of apatorsen in urothelial carcinoma (UC) (2 arms). Primary endpoint: Overall Survival at 36 months. Started Apr 2013; status: completed.
02
Drugs
apatorsen
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01780545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01780545.